Wen S - Search Results

1

CRISPR/Cas9 screening identifies a kinetochore-microtubule dependent mechanism for Aurora-A inhibitor resistance in breast cancer.

Chen A, Wen S, Liu F, Zhang Z, Liu M, Wu Y, He B, Yan M, Kang T, Lam EW, Wang Z, Liu Q. Chen A, et al. Among authors: wen s. Cancer Commun (Lond). 2021 Feb;41(2):121-139. doi: 10.1002/cac2.12125. Epub 2021 Jan 20. Cancer Commun (Lond). 2021. PMID: 33471959 Free PMC article.

2

Metabolic reprogramming and redox adaptation in sorafenib-resistant leukemia cells: detected by untargeted metabolomics and stable isotope tracing analysis.

You X, Jiang W, Lu W, Zhang H, Yu T, Tian J, Wen S, Garcia-Manero G, Huang P, Hu Y. You X, et al. Among authors: wen s. Cancer Commun (Lond). 2019 Apr 4;39(1):17. doi: 10.1186/s40880-019-0362-z. Cancer Commun (Lond). 2019. PMID: 30947742 Free PMC article.

3

Design, Synthesis, and Evaluation of VHL-Based EZH2 Degraders to Enhance Therapeutic Activity against Lymphoma.

Tu Y, Sun Y, Qiao S, Luo Y, Liu P, Jiang ZX, Hu Y, Wang Z, Huang P, Wen S. Tu Y, et al. Among authors: wen s. J Med Chem. 2021 Jul 22;64(14):10167-10184. doi: 10.1021/acs.jmedchem.1c00460. Epub 2021 Jul 1. J Med Chem. 2021. PMID: 34196564

4

A Temporal PROTAC Cocktail-Mediated Sequential Degradation of AURKA Abrogates Acute Myeloid Leukemia Stem Cells.

Liu F, Wang X, Duan J, Hou Z, Wu Z, Liu L, Lei H, Huang D, Ren Y, Wang Y, Li X, Zhuo J, Zhang Z, He B, Yan M, Yuan H, Zhang L, Yan J, Wen S, Wang Z, Liu Q. Liu F, et al. Among authors: wen s. Adv Sci (Weinh). 2022 Aug;9(22):e2104823. doi: 10.1002/advs.202104823. Epub 2022 Jun 2. Adv Sci (Weinh). 2022. PMID: 35652200 Free PMC article.

5

Wild-type IDH2 is a therapeutic target for triple-negative breast cancer.

Li JJ, Yu T, Zeng P, Tian J, Liu P, Qiao S, Wen S, Hu Y, Liu Q, Lu W, Zhang H, Huang P. Li JJ, et al. Among authors: wen s. Nat Commun. 2024 Apr 24;15(1):3445. doi: 10.1038/s41467-024-47536-6. Nat Commun. 2024. PMID: 38658533 Free PMC article.

6

Effective inhibition of nasopharyngeal carcinoma in vitro and in vivo by targeting glycolysis with oxamate.

Li X, Lu W, Hu Y, Wen S, Qian C, Wu W, Huang P. Li X, et al. Among authors: wen s. Int J Oncol. 2013 Nov;43(5):1710-8. doi: 10.3892/ijo.2013.2080. Epub 2013 Aug 27. Int J Oncol. 2013. PMID: 23982861

7

Xc- inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSH-dependent mechanism.

Ma MZ, Chen G, Wang P, Lu WH, Zhu CF, Song M, Yang J, Wen S, Xu RH, Hu Y, Huang P. Ma MZ, et al. Among authors: wen s. Cancer Lett. 2015 Nov 1;368(1):88-96. doi: 10.1016/j.canlet.2015.07.031. Epub 2015 Aug 5. Cancer Lett. 2015. PMID: 26254540

8

Metabolic alterations and drug sensitivity of tyrosine kinase inhibitor resistant leukemia cells with a FLT3/ITD mutation.

Huang A, Ju HQ, Liu K, Zhan G, Liu D, Wen S, Garcia-Manero G, Huang P, Hu Y. Huang A, et al. Among authors: wen s. Cancer Lett. 2016 Jul 28;377(2):149-57. doi: 10.1016/j.canlet.2016.04.040. Epub 2016 Apr 28. Cancer Lett. 2016. PMID: 27132990

9

Regulation of stem-like cancer cells by glutamine through β-catenin pathway mediated by redox signaling.

Liao J, Liu PP, Hou G, Shao J, Yang J, Liu K, Lu W, Wen S, Hu Y, Huang P. Liao J, et al. Among authors: wen s. Mol Cancer. 2017 Feb 28;16(1):51. doi: 10.1186/s12943-017-0623-x. Mol Cancer. 2017. PMID: 28245869 Free PMC article.

10

Targeting cancer cell mitochondria as a therapeutic approach: recent updates.

Cui Q, Wen S, Huang P. Cui Q, et al. Among authors: wen s. Future Med Chem. 2017 Jun;9(9):929-949. doi: 10.4155/fmc-2017-0011. Epub 2017 Jun 21. Future Med Chem. 2017. PMID: 28636410 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,960 results

Search Page

Filters